Cargando…

Dosimetric impact of simulated changes in large bowel content during proton therapy with simultaneous integrated boost for locally advanced pancreatic cancer

PURPOSE: To investigate the dosimetric impact of changes in the large bowel content during proton therapy (PT) with simultaneous integrated boost (SIB) for locally advanced pancreatic cancer (LAPC). MATERIALS AND METHODS: Fifteen patients with LAPC were included in this study. The SIB method was per...

Descripción completa

Detalles Bibliográficos
Autores principales: Narita, Yuki, Kato, Takahiro, Takemasa, Kimihiro, Sato, Hiroki, Ikeda, Tomohiro, Harada, Takaomi, Oyama, Sho, Murakami, Masao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598140/
https://www.ncbi.nlm.nih.gov/pubmed/34599856
http://dx.doi.org/10.1002/acm2.13429
_version_ 1784600750198882304
author Narita, Yuki
Kato, Takahiro
Takemasa, Kimihiro
Sato, Hiroki
Ikeda, Tomohiro
Harada, Takaomi
Oyama, Sho
Murakami, Masao
author_facet Narita, Yuki
Kato, Takahiro
Takemasa, Kimihiro
Sato, Hiroki
Ikeda, Tomohiro
Harada, Takaomi
Oyama, Sho
Murakami, Masao
author_sort Narita, Yuki
collection PubMed
description PURPOSE: To investigate the dosimetric impact of changes in the large bowel content during proton therapy (PT) with simultaneous integrated boost (SIB) for locally advanced pancreatic cancer (LAPC). MATERIALS AND METHODS: Fifteen patients with LAPC were included in this study. The SIB method was performed using five fields according to our standard protocol. A total dose of 67.5 Gy(relative biological effectiveness [RBE]) was prescribed in 25 fractions using the SIB method. A dose of 45 Gy(RBE) was prescribed for the entire planning target volume (PTV) by using four main fields. The remaining 22.5 Gy(RBE) was prescribed to the PTV excluding for the gastrointestinal tract using one subfield. Five simulated doses were obtained by the forward dose calculations with the Hounsfield units (HU) override to the large bowel to 50, 0, −100, −500, and −1000, respectively. The dose‐volume indices in each plan were compared using the 50 HU plan as a reference. RESULTS: At D(98) of the clinical target volume (CTV) and spinal cord‐D(2cc), when the density of the large bowel was close to that of gas, there were significant differences compared to the reference plan (p < 0.05). By contrast, no significant difference was observed in stomach‐D(2cc) duodenum‐D(2cc), small bowel‐D(2cc), kidneys‐V(18), and liver‐D(mean) under any of the conditions. There were no cases in which the dose constraint of organs at risk, specified by our institution, was exceeded. CONCLUSION: Density change in the large bowel was revealed to significantly affect the doses of the CTV and spinal cord during PT with SIB for LAPC. For beam arrangement, it is important to select a gantry angle that prevents the large bowel from passing as much as possible. If this is unavoidable, it is important to carefully observe the gas image on the beam path during daily image guidance and to provide adaptive re‐planning as needed.
format Online
Article
Text
id pubmed-8598140
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-85981402021-12-02 Dosimetric impact of simulated changes in large bowel content during proton therapy with simultaneous integrated boost for locally advanced pancreatic cancer Narita, Yuki Kato, Takahiro Takemasa, Kimihiro Sato, Hiroki Ikeda, Tomohiro Harada, Takaomi Oyama, Sho Murakami, Masao J Appl Clin Med Phys Radiation Oncology Physics PURPOSE: To investigate the dosimetric impact of changes in the large bowel content during proton therapy (PT) with simultaneous integrated boost (SIB) for locally advanced pancreatic cancer (LAPC). MATERIALS AND METHODS: Fifteen patients with LAPC were included in this study. The SIB method was performed using five fields according to our standard protocol. A total dose of 67.5 Gy(relative biological effectiveness [RBE]) was prescribed in 25 fractions using the SIB method. A dose of 45 Gy(RBE) was prescribed for the entire planning target volume (PTV) by using four main fields. The remaining 22.5 Gy(RBE) was prescribed to the PTV excluding for the gastrointestinal tract using one subfield. Five simulated doses were obtained by the forward dose calculations with the Hounsfield units (HU) override to the large bowel to 50, 0, −100, −500, and −1000, respectively. The dose‐volume indices in each plan were compared using the 50 HU plan as a reference. RESULTS: At D(98) of the clinical target volume (CTV) and spinal cord‐D(2cc), when the density of the large bowel was close to that of gas, there were significant differences compared to the reference plan (p < 0.05). By contrast, no significant difference was observed in stomach‐D(2cc) duodenum‐D(2cc), small bowel‐D(2cc), kidneys‐V(18), and liver‐D(mean) under any of the conditions. There were no cases in which the dose constraint of organs at risk, specified by our institution, was exceeded. CONCLUSION: Density change in the large bowel was revealed to significantly affect the doses of the CTV and spinal cord during PT with SIB for LAPC. For beam arrangement, it is important to select a gantry angle that prevents the large bowel from passing as much as possible. If this is unavoidable, it is important to carefully observe the gas image on the beam path during daily image guidance and to provide adaptive re‐planning as needed. John Wiley and Sons Inc. 2021-10-02 /pmc/articles/PMC8598140/ /pubmed/34599856 http://dx.doi.org/10.1002/acm2.13429 Text en © 2021 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, LLC on behalf of The American Association of Physicists in Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Radiation Oncology Physics
Narita, Yuki
Kato, Takahiro
Takemasa, Kimihiro
Sato, Hiroki
Ikeda, Tomohiro
Harada, Takaomi
Oyama, Sho
Murakami, Masao
Dosimetric impact of simulated changes in large bowel content during proton therapy with simultaneous integrated boost for locally advanced pancreatic cancer
title Dosimetric impact of simulated changes in large bowel content during proton therapy with simultaneous integrated boost for locally advanced pancreatic cancer
title_full Dosimetric impact of simulated changes in large bowel content during proton therapy with simultaneous integrated boost for locally advanced pancreatic cancer
title_fullStr Dosimetric impact of simulated changes in large bowel content during proton therapy with simultaneous integrated boost for locally advanced pancreatic cancer
title_full_unstemmed Dosimetric impact of simulated changes in large bowel content during proton therapy with simultaneous integrated boost for locally advanced pancreatic cancer
title_short Dosimetric impact of simulated changes in large bowel content during proton therapy with simultaneous integrated boost for locally advanced pancreatic cancer
title_sort dosimetric impact of simulated changes in large bowel content during proton therapy with simultaneous integrated boost for locally advanced pancreatic cancer
topic Radiation Oncology Physics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598140/
https://www.ncbi.nlm.nih.gov/pubmed/34599856
http://dx.doi.org/10.1002/acm2.13429
work_keys_str_mv AT naritayuki dosimetricimpactofsimulatedchangesinlargebowelcontentduringprotontherapywithsimultaneousintegratedboostforlocallyadvancedpancreaticcancer
AT katotakahiro dosimetricimpactofsimulatedchangesinlargebowelcontentduringprotontherapywithsimultaneousintegratedboostforlocallyadvancedpancreaticcancer
AT takemasakimihiro dosimetricimpactofsimulatedchangesinlargebowelcontentduringprotontherapywithsimultaneousintegratedboostforlocallyadvancedpancreaticcancer
AT satohiroki dosimetricimpactofsimulatedchangesinlargebowelcontentduringprotontherapywithsimultaneousintegratedboostforlocallyadvancedpancreaticcancer
AT ikedatomohiro dosimetricimpactofsimulatedchangesinlargebowelcontentduringprotontherapywithsimultaneousintegratedboostforlocallyadvancedpancreaticcancer
AT haradatakaomi dosimetricimpactofsimulatedchangesinlargebowelcontentduringprotontherapywithsimultaneousintegratedboostforlocallyadvancedpancreaticcancer
AT oyamasho dosimetricimpactofsimulatedchangesinlargebowelcontentduringprotontherapywithsimultaneousintegratedboostforlocallyadvancedpancreaticcancer
AT murakamimasao dosimetricimpactofsimulatedchangesinlargebowelcontentduringprotontherapywithsimultaneousintegratedboostforlocallyadvancedpancreaticcancer